Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash & Current Investments (2016 - 2025)

Collegium Pharmaceutical has reported Cash & Current Investments over the past 10 years, most recently at $251.1 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $251.1 million for Q4 2025, up 162.76% from a year ago — trailing twelve months through Dec 2025 was $251.1 million (up 162.76% YoY), and the annual figure for FY2025 was $251.1 million, up 162.76%.
  • Cash & Current Investments for Q4 2025 was $251.1 million at Collegium Pharmaceutical, down from $285.9 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for COLL hit a ceiling of $325.5 million in Q2 2023 and a floor of $95.6 million in Q4 2024.
  • Median Cash & Current Investments over the past 5 years was $200.3 million (2021), compared with a mean of $213.7 million.
  • Biggest five-year swings in Cash & Current Investments: surged 165.21% in 2023 and later crashed 69.23% in 2024.
  • Collegium Pharmaceutical's Cash & Current Investments stood at $186.4 million in 2021, then dropped by 6.83% to $173.7 million in 2022, then skyrocketed by 78.8% to $310.5 million in 2023, then crashed by 69.23% to $95.6 million in 2024, then surged by 162.76% to $251.1 million in 2025.
  • The last three reported values for Cash & Current Investments were $251.1 million (Q4 2025), $285.9 million (Q3 2025), and $222.2 million (Q2 2025) per Business Quant data.